TY - JOUR T1 - The outcome of broncho-dilation among subjects with airway obstruction in the general population JF - European Respiratory Journal JO - Eur Respir J VL - 44 IS - Suppl 58 SP - P4757 AU - Sami Sawalha AU - Linnea Hedman AU - Eva Rönmark AU - Bo Lundbäck AU - Anne Lindberg Y1 - 2014/09/01 UR - http://erj.ersjournals.com/content/44/Suppl_58/P4757.abstract N2 - Background: Airway obstruction in COPD is defined as FEV1/(F)VC<0.70 after broncho-dilator. There are hardly any population-based data evaluating the clinical impact of the pre- and post bronchodilator quotation.Aim: To compare subjects with pre- but not post respectively pre- and post bronchodilator quotation FEV1/(F)VC<0.70 in the population.Methods: In 2002-04 all previously examined subjects from four adult OLIN (Obstructive Lung disease in Northern Sweden) cohorts were invited to re-examination including spirometry and structured interview. All subjects with FEV1/best of FVC and VC<0.70 were identified (n=993). Clinical characteristics were based on interview data.Results: After bronchodilator 736 subjects had FEV1/(F)VC<0.70 and 257 had a quotation >0.70. Those with quotation <0.70 were older than those with quotation >0.70 (64.4 vs. 63.3, p=0.012). There were no significant differences in sex, prevalence ever smokers, allergic rhinitis, physician diagnosis of asthma before the age of 40 or exacerbations during the last 12 months between the groups. Prevalence of heart disease and cardiovascular disease was also similar. Reversibility, FEV1+12%&≥200ml, was significantly more common among those with quotation >0.70 (22.6 vs. 8.8%, p<0.001), while productive cough and chronic bronchitis was more common among those with quotation <0.70 (45.9 vs. 33.9% and 41.4 vs. 30.4%, p= 0.002 and 0.001).Conclusion: Subjects with pre- but not post-bronchodilator quotation <0.70 have similar characteristics as those with post-bronchodilator quotation <0.70, but they may include more asthmatics. Further, the fairly common bronchitis symptoms among them may be markers of risk to develop COPD. ER -